Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine for Impulse Control Disorders in Parkinson's Disease
NCT03552068Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in impulse control disorder (ICD) comparing Placebo with Clonidine (2 arms). Primary endpoint: Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease - Rating Scale at 8 weeks. Started May 2019; status: completed.
02
Drugs
clonidine
03
Conditions
impulse control disorder (ICD)
Beyond the preview
Go deeper on NCT03552068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552068.